GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Net Interest Income

Suven Pharmaceuticals (BOM:543064) Net Interest Income : ₹-71 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Suven Pharmaceuticals's net interest income for the three months ended in Sep. 2024 was ₹-17 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-71 Mil.

Suven Pharmaceuticals Net Interest Income Historical Data

The historical data trend for Suven Pharmaceuticals's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Net Interest Income Chart

Suven Pharmaceuticals Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Interest Income
Get a 7-Day Free Trial -227.06 -113.98 -84.59 -69.79 -54.36

Suven Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.40 -12.69 -25.17 -16.00 -16.70

Suven Pharmaceuticals Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suven Pharmaceuticals Net Interest Income Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Suven Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Net Interest Income
Comparable Companies
NSE:GLAND BOM:506943 BOM:540222 BOM:544210 BOM:543635 BOM:524816 BOM:532300 BOM:532331 BOM:533573 BOM:524742 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
SUVENPHAR:India
Address
No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081
Website
https://www.suvenpharm.com
Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Suven Pharmaceuticals Headlines

No Headlines